Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

This publication has 56 references indexed in Scilit:

• Blood Pressure Lowering in Type 2 Diabetes
  JAMA, 2015
• Blood pressure lowering and cardiovascular risk – Authors' reply
  The Lancet, 2014
• Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study
  Diabetology International, 2014
• Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
  The Lancet, 2014
• Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)
  Canadian Journal of Diabetes, 2013
• Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
  Diabetologia, 2013
• Intensive glucose control and macrovascular outcomes in type 2 diabetes
  Diabetologia, 2009
• The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
  BMJ, 2009
• Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
  Controlled Clinical Trials, 1996
• Meta-analysis in clinical trials
  Controlled Clinical Trials, 1986